Open AccessAnti-PD-1 antibodies plus lenvatinib in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world patients
Author(s) -
Jixue Zou,
Peixin Huang,
Ningling Ge,
Xin Xu,
Yanhong Wang,
Lan Zhang,
Yi Chen
Publication year - 2022
Publication title -
journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.084
H-Index - 39
eISSN - 2219-679X
pISSN - 2078-6891
DOI - 10.21037/jgo-22-643
Subject(s) - lenvatinib , medicine , adverse effect , hepatocellular carcinoma , interquartile range , oncology , nivolumab , sorafenib , tolerability , gastroenterology , cancer , immunotherapy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom